Breast Implants Lymphoma Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implants associated with lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
Since our previous article regarding the connection between textured breast implants and Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), additional information on understanding the disease and its treatment has surfaced.
Background on BIA-ALCL and Recent Legislation
While the cause of BIA-ALCL was initially believed to be from a biofilm on the implant, current research is unclear how big of a role it plays in the disease. Specific textured devices, such as the Allergan Biocell textured implants, have a much higher association with BIA-ALCL. You can refer to our article on the topic, “U.S. FDA Refrains from Textured Implants Ban“, for more information on textured breast implants.
To read more of this article, click below:
Current Treatment Options
In a May 2020 OncLive article, “Breast Implant-Associated ALCL Understanding and Treatment Evolves“, Dr. Lloyd B. Gayle addressed the current treatment options as well as what the future holds for BIA-ALCL patients. Dr. Gayle is the director of Plastic Surgery Resident Education and associate professor of clinical surgery at Weill Cornell Medical College,
Breast implant–associated ALCL is a relatively new entity, so treatment modalities are evolving. The cornerstone to this is understanding that with early diagnosis, specifically in patients with stage I/II disease where there is no spread beyond the breast, the capsule, and the surrounding soft tissue, treatment is best rendered with a total capsulectomy. [Total capsulectomy] is now defined as an unblocked resection, which is to say the removal of the implant, the surrounding capsule, and any surrounding mass within the soft tissue.
As the understanding we have of the disease grows, treatment for BIA-ALCL is becoming more interdisciplinary. Currently, radiation therapy and chemotherapy are used in combination with a total capsulectomy. Many patients also see several doctors, who work collaboratively to administer treatment.
What the Future Holds
Moving forward, it is important to keep up-to-date on BIA-ALCL information as more research is being done. In the recent OncLive article, Dr. Lloyd B. Gayle highlights the current treatment recommendations,
Textured devices from Allergen have been voluntarily removed from the marketplace. The current recommendation is to not preemptively remove these devices from patients unless they present with symptoms, or unless they have other drivers such as capsular contracture, aesthetic concerns, or implant rupture. In those cases, you should proceed with implant removal.[Read article in full at original source]
Our earlier articles about this breast implants lymphoma cancer situation:
- Cancer Linked to Breast Implants: Is it Considered Rare Anymore?
- FDA Proposes New Recommendations for Breast Implant Labels
- TGA Regulations on Breast Implant Products
- FDA Recalls Allergan Textured Implants
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer